Early Diagnosis and Augmentation for Alpha-1 Antitrypsin Deficiency Lung Disease: A Care Team Forum℠

Program Overview

This activity is designed to engage your critical thinking about patients who may have alpha-1 antityrypsin deficiency (AATD) and to challenge suboptimal approaches to the management of patients with AATD lung disease. You will hear unique insights from 3 clinical experts and a patient living with AATD during this dynamic presentation.

Credit Expired
CE Credit Expired
Expires: September 12, 2020

Target Audience

The target audience for this activity is clinicians who can impact the recognition and management of patients with alpha-1 antityrypsin deficiency (AATD) lung disease.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Demonstrate improved ability to identify alpha-1 antityrypsin deficiency (AATD) in their patients affected by chronic obstructive pulmonary disease (COPD)
  • Identify patients at risk for AATD and implement guideline-recommended testing
  • Discuss the efficacy data and guideline recommendations for augmentation therapy used to treat AATD
  • Develop individualized treatment plans for patients with AATD using all available clinical information about the patient, including information about physiological health status

Activity Faculty

Robert A. Sandhaus, MD, PhD, FCCP (Chair)

Professor, Medicine
Director , Alpha-1 Program
Division of Pulmonary, Critical Care, and Sleep Medicine
National Jewish Health
Denver, CO

Supporter Statement

Provider Statement

Disclosure of Financial Relationships


Planners and Managers

Method of Participation and Request for Credit

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 

Disclaimer Statement

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 

Copyright Statement

© Copyright 2024. All rights reserved. Developed and managed by RMEI Medical Education, LLC. Laurel Office Plaza | 101 Laurel Road, Suite 200 | Voorhees, NJ 08043 | www.RMEI.com | (866) 770-RMEI


Stay up to date with the latest RMEI CE Activities and receive Exclusive Medical Education Resources